WHO Expert Committee on Specifications for Pharmaceutical Preparations

World Health Organization - Technical Report Series

Volumn , Issue 908, 2003, Pages

  Addae Mensah, I ^a   Bremer, K ^b   Haggag, A A ^c   Shaohong, Jin ^d   Poompanich, A ^e   Tribe, R W ^f   Miller, J H McB ^g   Ruiz, H V ^h   Morin, O ⁱ   Rafidison, P ^j   Ha, Thuy Huong ^k   Reinstein, J A ^l   Moraes da Silva, A B ^m   Balocco Mattavelli, R ⁿ   Chisale, M ^o   Dansereau, F ^p   Ehrin, E ^q   Griffiths, E ⁿ   Kopp, S ⁿ   Maruyama, Y ⁿ   Morimoto, K ⁿ   Munderi, P ⁿ   Njau, E ^x   Ondari, C ⁿ   Padilla, A M ⁿ   Phanouvong, S ^p   Ponce D'Leon L F ^r   Quick, J D ⁿ   Rago L ⁿ   Reggi, V ⁿ   Kumar, A ^s   Santoso, B ^t   Weerasuriya, K ^u   Sur, S ^v   Suzuki, Y ⁿ   Tamiya, K ⁿ   Vanbel, P ⁿ   Van Zyl, A ⁿ   Vareldzis, B ⁿ   Williams, R L ^w   Wondemagegnehu, E ⁿ   Zhang, X ⁿ   more..

^a UNIVERSITY OF GHANA   (Ghana)

^b Norwegian Med Control Authority   (Norway)

^c TANTA UNIVERSITY   (Egypt)

^d Natl Inst Ctrl Pharm Biol Prod   (China)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^g European Network of National Information Centers   (France)

^h Industrial Applications Section   (Austria)

ⁱ IFPMA   (Switzerland)

^j International Pharmaceutical Excipients Council (IPEC)   (United Kingdom)

^k UNICEF   (United States)

^l WSMI   (United Kingdom)

^m INSTITUTO OSWALDO CRUZ   (Brazil)

ⁿ WORLD HEALTH ORGANIZATION   (Switzerland)

^o WHO Regional Office for Africa   (Zimbabwe)

^p OCPC   (Canada)

^q WHO Collab Ctr Chem Ref Subst   (Sweden)

^r UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^s Health Services   (India)

^t The World Health Organization Regional Office for the Western Pacific philippines   (Philippines)

^u WHO Regional Office for South East Asia   (India)

^v Ministry of Health of Ukraine   (Ukraine)

^w UNITED STATES PHARMACOPEIA   (United States)

^x NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ETHAMBUTOL; HERBACEOUS AGENT; ISONIAZID; PYRAZINAMIDE; RADIOPHARMACEUTICAL AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOEQUIVALENCE; BRAIN SPONGIOSIS; CERTIFICATION; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG CONTROL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG IMPURITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG NOMENCLATURE; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; GOOD MANUFACTURING PRACTICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALARIA; MEDICAL LITERATURE; POLICY; QUALITY CONTROL; RISK ASSESSMENT; STANDARD; THIN LAYER CHROMATOGRAPHY; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 0037833463     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (2)

1. Provisional guidelines on the inspection of pharmaceutical manufacturers. In: WHO Expert Committee on Specifications of Pharmaceutical Preparations. Thirty-Second report. Geneva, World Health Organization, 1992, Annex 2 (WHO Technical Report Series, No. 823).
2. Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms. In: WHO Expert Committee on Specifications of Pharmaceutical Preparations. Thirty-Fourth report. Geneva, World Health Organization, 1996, Annex 5 (WHO Technical Report Series, No. 863).